NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-09-29 18:47இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
CARE Upgrades Innova Captab's Credit Ratings: Long-Term to CARE A+, Short-Term to CARE A1+
CARE Ratings has upgraded Innova Captab Limited's credit ratings on total bank facilities of Rs 459.60 crore. Long-term bank facilities of Rs 419.60 crore (reduced from Rs 426.72 crore) were upgraded from 'CARE A; Positive' to 'CARE A+; Stable'. Short-term bank facilities of Rs 40.00 crore were upgraded from 'CARE A1' to 'CARE A1+'. The rating revision reflects the operational and financial performance evaluated by CARE for FY26 and Q1FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுCARE Ratings revised Innova Captab's long-term credit rating up by one notch to CARE A+ (Stable) and short-term rating to CARE A1+.
ஏன் இது முக்கியம்A higher rating improves the company's creditworthiness, potentially lowering its financing costs across its Rs 459.60 crore in rated banking facilities.
Total rated facilities: Rs.459.60 croreLong-term bank facilities: 419.60 கோடிShort-term bank facilities: 40.00 கோடிRated facilities vs TTM revenue: ~8.0%
📅 குறுகிய காலம்Positive sentiment for the stock as rating upgrades indicate strengthening balance sheet stability and operational health.
📈 நீண்ட காலம்Enhances borrowing capacity and lowers interest expense profile as the company expands operations in Jammu and international markets.
👀 கவனிக்க வேண்டியவை
Monitor whether the upgraded credit rating leads to lower borrowing costs and improved working capital terms in upcoming quarterly financials.
Innova Captab approves brownfield expansion at Baddi plant and revises FY26 audited results
Innova Captab Limited's Board of Directors has approved a brownfield expansion of its existing manufacturing facility located at Baddi, Himachal Pradesh. Additionally, the Board approved revised audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The statutory auditor, B S R & Co. LLP, issued an unmodified audit opinion on the revised consolidated annual results. The expansion aims to boost manufacturing throughput within the existing premises.
நடுத்தரம் நம்பிக்கை
என்ன மாறியதுInnova Captab approved a brownfield manufacturing capacity expansion at Baddi and adopted revised audited annual financial statements for FY26.
ஏன் இது முக்கியம்The brownfield expansion within existing premises enables incremental CDMO and formulations production capacity with lower lead time and capex compared to greenfield setups.
📅 குறுகிய காலம்Market sentiment is likely to view the expansion approval favorably, while investors review the detailed notes to assess reasons behind the FY26 financial revisions.
📈 நீண்ட காலம்Enhances manufacturing scale to support company's stated generic formulations and CDMO growth pipeline alongside the recently operationalized Kathua facility.
⚠ அபாய எச்சரிக்கைகள்
Execution timeline and cost escalation risks for brownfield construction
Reasons for revising full-year audited financial results warrant monitoring
👀 கவனிக்க வேண்டியவை
Track subsequent disclosures regarding the specific capex outlay, capacity addition metrics, and commissioning timelines for the Baddi brownfield expansion.
Innova Captab Q1 Concall: Revenue Up 34% YoY to ₹470.9 Cr, PAT Rises 42% to ₹44.1 Cr
Innova Captab delivered strong Q1 FY27 results with consolidated revenue increasing 34% YoY to ₹470.9 Cr, driven by robust performance across both CDMO (₹328.7 Cr, +32% YoY) and branded generics (₹142.2 Cr, +39% YoY). EBITDA rose 33% YoY to ₹75.1 Cr with a 16.0% margin, while PAT expanded 42% YoY to ₹44.1 Cr. Management reiterated full-year FY27 guidance of 20%+ volume-led revenue growth with profitability expected to outpace revenue. The new Jammu manufacturing facility is currently operating at 25%-30% capacity utilization on an annualized basis, with management targeting >₹1,000 Cr in revenue at steady-state utilization.
உச்சம் நம்பிக்கை
என்ன மாறியதுInnova Captab published the detailed transcript of its Q1 FY27 earnings call held on August 12, 2026.
ஏன் இது முக்கியம்Demonstrates sustained operating leverage in core CDMO operations and provides clear operational milestones for the newly commissioned Jammu plant.
📅 குறுகிய காலம்Positive sentiment driven by healthy 42% PAT growth and reaffirmation of 20%+ revenue growth guidance for FY27.
📈 நீண்ட காலம்Ramping up the Jammu greenfield unit to >₹1,000 Cr revenue and securing global product approvals provide strong structural growth visibility.
⚠ அபாய எச்சரிக்கைகள்
Execution and regulatory approval timelines for new product filings at the Jammu plant
Volatility in raw material/API prices impacting contract margins
👀 கவனிக்க வேண்டியவை
Monitor quarterly capacity ramp-up and international regulatory approvals for the Jammu facility to verify sustained 20%+ growth delivery.
34% Revenue Growth in Q1 FY27: Innova Captab Ramps Up Jammu Facility and CDMO Segment
Innova Captab reported a strong start to FY27 with Q1 revenue growing 34% YoY to ₹470.9 Cr, driven by robust performance in both CDMO (+32%) and Branded Generics (+39%) segments. The company is benefiting from the ramp-up of its Jammu facility, which was commercialized in January 2025, and recent global certifications from UK-MHRA and PIC/S. Consolidated FY26 revenue reached ₹1,630 Cr with an EBITDA margin of 15.4%. The CDMO segment remains the primary growth engine, contributing approximately 70% of total quarterly revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has successfully transitioned its new Jammu facility into commercial operations, leading to a significant 34% YoY revenue jump in the first quarter of FY27.
ஏன் இது முக்கியம்The expansion and recent international regulatory approvals (UK-MHRA) allow the company to target higher-margin regulated markets and larger global CDMO contracts, potentially re-rating its growth profile.
📅 குறுகிய காலம்Positive sentiment is expected due to strong double-digit growth across all business segments and successful regulatory inspections, which validates the company's quality standards.
📈 நீண்ட காலம்Structural growth is supported by the Jammu plant's capacity and expansion into regulated markets like the UK and Ukraine, diversifying the revenue base beyond domestic CDMO.
⚠ அபாய எச்சரிக்கைகள்
Working capital pressure due to increased inventory for the Jammu plant
API price volatility impacting CDMO contract values
👀 கவனிக்க வேண்டியவை
Investors should monitor the utilization rates and margin progression of the Jammu facility as it scales. The impact of recent UK-MHRA and PIC/S (Ukraine) certifications on international order flows will be a key metric for long-term growth.
Innova Captab Q1 Standalone PAT Jumps 58% to ₹32.06 Cr; FY26 Financials to be Revised
Innova Captab reported a strong standalone performance for Q1 FY27 (ending June 2026), with revenue rising 39.5% YoY to ₹400.48 Cr. Standalone PAT grew 58% YoY to ₹32.06 Cr, driven by operational scaling. However, the company disclosed that 'inadvertent errors' were identified in the previously approved FY26 financial statements (both standalone and group), necessitating a formal revision. While management claims no material impact on Q1 FY27 results, the revision details are pending the next board meeting.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its Q1 FY27 earnings and simultaneously announced a pending revision of its audited FY26 financial statements due to identified errors.
ஏன் இது முக்கியம்Strong double-digit growth in the standalone CDMO business confirms operational momentum, but the revision of audited financials is a governance monitorable that could affect investor sentiment.
Standalone Revenue (Q1 FY27): ₹400.48 கோடிStandalone PAT (Q1 FY27): ₹32.06 கோடிYoY Revenue Growth: 39.5%YoY PAT Growth: 58.0%Q1 Revenue vs TTM Consolidated Revenue: ~7.1%
📅 குறுகிய காலம்The strong earnings growth is a positive catalyst, but the disclosure of accounting errors in FY26 may lead to short-term volatility until the revised statements are published.
📈 நீண்ட காலம்The company's expansion into international markets (UK-MHRA, Ukraine) and the Jammu facility ramp-up remain the primary long-term value drivers, provided governance standards remain stable.
⚠ அபாய எச்சரிக்கைகள்
Revision of previously audited financial statements due to errors
Rising finance costs (up 45.7% YoY)
Potential impact of API price volatility on CDMO margins
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming board meeting for the specific nature and magnitude of the FY26 financial revisions. While operational growth is robust, the accounting errors require clarity to ensure financial reporting integrity.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Innova Captab FY26 Revenue Up 31% to ₹1,630 Cr; AGM Scheduled for June 29, 2026
Innova Captab has released its FY 2025-26 Integrated Annual Report and scheduled its 22nd AGM for June 29, 2026. The company delivered robust financial performance with revenue growing 31.1% YoY to ₹1,630.02 crore and EBITDA rising 26.3% to ₹250.34 crore. Operational highlights include the successful commercialization of the Kathua facility and obtaining UK-MHRA certification for the Baddi plant. The company also declared an interim dividend of ₹2 per share during the fiscal year.
முக்கிய அம்சங்கள்
Revenue from operations increased 31.1% YoY to ₹1,630.02 crore in FY26.EBITDA grew 26.3% to ₹250.34 crore, while PAT rose 9.9% to ₹140.92 crore.Export contribution reached 31.3% across 60+ global markets with 4,200+ products.Received UK-MHRA GMP compliance for Baddi and PIC/S compliance for the Kathua facility.Interim dividend of ₹2 per share declared for the financial year.
👀 கவனிக்க வேண்டியவை
Investors should monitor the capacity utilization and margin profile of the new Kathua facility as it ramps up. The company's expanding global certifications and 31% revenue growth position it well in the CDMO and branded generics space.
Innova Captab Re-appoints MD, WTD, and Statutory Auditors for 5-Year Terms
Innova Captab's board has approved the re-appointment of key leadership, including Managing Director Vinay Lohariwala and Whole-Time Director Manoj Kumar Lohariwala, for second five-year terms starting March 2027. The company also extended the tenure of B S R & Co. LLP as statutory auditors for another five years until FY 2030-31. Additionally, four independent directors were re-appointed for five-year terms, ensuring board stability through 2032. These appointments are subject to shareholder approval at the upcoming 22nd Annual General Meeting.
முக்கிய அம்சங்கள்
Re-appointment of MD Vinay Lohariwala and WTD Manoj Kumar Lohariwala for 5-year terms (2027-2032)Statutory Auditor B S R & Co. LLP re-appointed for a second 5-year term (FY 2026-27 to 2030-31)Grant Thornton Bharat LLP re-appointed as Internal Auditors for the financial year 2026-27Four Independent Directors re-appointed for 5-year terms starting April 1, 2027
👀 கவனிக்க வேண்டியவை
The re-appointment of the founding leadership and reputable audit firms suggests operational and governance continuity. Investors should monitor the upcoming AGM for final shareholder approval of these resolutions.
Innova Captab Limited reported a strong financial performance for FY26, with consolidated revenue rising 31% YoY to ₹1,630 crores. The growth was spearheaded by the Branded Generics segment, which surged 51% to ₹497 crores, while the core CDMO business grew 24% to ₹1,133 crores. Management has guided for a 20% plus revenue growth in the coming years, with expectations that EBITDA and PAT will grow faster than revenue due to operating leverage from the newly ramped-up Jammu facility. The company also achieved significant regulatory milestones, including UK-MHRA and PIC/S certifications, positioning it for regulated international market expansion.
முக்கிய அம்சங்கள்
FY26 Consolidated Revenue grew 31% YoY to ₹1,630 crores, with Q4 revenue up 42% to ₹448 crores.Branded Generics segment delivered robust 51% growth, contributing ₹497 crores to total revenue.CDMO business revenue reached ₹1,133 crores, supported by a customer base of over 350 clients.Full-year EBITDA stood at ₹250.3 crores with a 15.4% margin; PAT grew 10% to ₹140.9 crores.Exports contributed 31% to total FY26 revenue, aided by new international regulatory approvals.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's ability to maintain its 20%+ growth guidance and the expected margin expansion as the Jammu facility reaches higher utilization. The successful regulatory approvals in the UK and Ukraine provide a strong catalyst for higher-margin export growth in the medium term.
Innova Captab reported a strong performance for FY26 with consolidated revenue growing 31% YoY to ₹1,630 crore, led by a massive 51% jump in the Branded Generics segment. While EBITDA grew 26% to ₹250.3 crore, PAT margins compressed slightly to 8.6% from 10.3% due to increased depreciation and finance costs following the Jammu plant commercialization. The company is successfully ramping up its new Jammu facility (10-15% current utilization) and has secured key international certifications like UK-MHRA and PIC/S, which are expected to drive export growth in regulated markets.
முக்கிய அம்சங்கள்
Annual revenue reached a record ₹1,630 crore (+31% YoY) with Q4 FY26 revenue growing 42% YoY to ₹447.8 crore.Branded Generics business outperformed with 51% annual growth, while CDMO services grew by 24% to ₹1,133.4 crore.Jammu facility completed its first full year of operations; utilization is targeted to reach 70-75% over the next 5-6 years.Secured UK-MHRA certification for Baddi facility and PIC/S compliance for Jammu, enhancing global market access.Consolidated EBITDA for FY26 stood at ₹250.3 crore with a margin of 15.4%.
👀 கவனிக்க வேண்டியவை
Investors should focus on the utilization ramp-up at the Jammu facility and the potential for margin expansion as operating leverage kicks in. The company's shift toward regulated markets and branded generics provides a strong long-term growth trajectory.
Innova Captab Q4 FY26 Revenue Surges 42% YoY to ₹447.8 Cr; FY26 PAT at ₹140.9 Cr
Innova Captab reported a strong top-line growth of 42.3% YoY in Q4 FY26, reaching ₹447.8 crores, driven by momentum in its CDMO and branded generics segments. While EBITDA grew 30.5% to ₹66.7 crores, margins saw a contraction of 130 bps to 14.9% during the quarter. For the full year FY26, the company achieved its highest-ever revenue of ₹1,630 crores, a 31.1% increase over FY25. The company also secured key international certifications including UK-MHRA and PIC/S, positioning it for expansion in regulated global markets.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue grew 42.3% YoY to ₹447.8 Cr; FY26 Revenue reached record ₹1,630 Cr (+31.1%).Q4 PAT increased by 28.8% YoY to ₹38.1 Cr, while full-year PAT grew 9.9% to ₹140.9 Cr.EBITDA margins contracted slightly from 16.2% to 14.9% in Q4 and from 15.9% to 15.4% for FY26.Secured UK-MHRA certification for Baddi facility and PIC/S for Jammu blocks to boost export potential.Jammu facility completed its first full year of operations and is ramping up with marquee clients.
👀 கவனிக்க வேண்டியவை
Investors should focus on the robust revenue growth and the successful ramp-up of the Jammu facility, while monitoring the slight compression in EBITDA margins. The company remains a strong growth play in the CDMO space with improving regulatory credentials for international markets.
Innova Captab Limited's Board of Directors has approved the audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026. The statutory auditors, B S R & Co. LLP, issued an unmodified opinion, confirming the financial statements provide a true and fair view of the company's performance. The consolidated results include performance from subsidiaries such as Univentis Medicare Limited and Sharon Bio-Medicine Limited. Additionally, the board updated the company's Related Party Transactions policy to maintain regulatory compliance.
முக்கிய அம்சங்கள்
Board approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.Statutory auditors issued a declaration of Unmodified Opinion, signifying clean financial reporting.The consolidated entity includes key subsidiaries Univentis Medicare and Sharon Bio-Medicine Limited.One subsidiary reported total assets of Rs. 0.34 million and a net loss of Rs. 0.43 million for the year.Board approved amendments to the Policy on dealing with Related Party Transactions to align with current laws.
👀 கவனிக்க வேண்டியவை
Investors should examine the full financial tables on the company's website to evaluate specific growth metrics in revenue and PAT. The clean audit report is a positive sign of corporate governance and financial transparency.
Innova Captab Credit Rating Reaffirmed at 'CARE A; Positive' with Enhanced Limits to ₹466.72 Cr
CARE Ratings has reaffirmed Innova Captab's long-term rating at 'CARE A' while maintaining a 'Positive' outlook, suggesting potential for a future upgrade. The company's total rated bank facilities have been enhanced to ₹466.72 crore, up from ₹409.38 crore previously. Short-term facilities were also reaffirmed at 'CARE A1', reflecting strong liquidity and creditworthiness. This rating action is based on the company's audited FY25 and 9MFY26 performance, indicating sustained financial stability and operational growth.
முக்கிய அம்சங்கள்
Long-term rating reaffirmed at 'CARE A' with a 'Positive' outlook for ₹426.72 crore facilities.Short-term rating reaffirmed at 'CARE A1' for ₹40.00 crore facilities.Total bank facility limits enhanced by ₹57.34 crore to a total of ₹466.72 crore.Rating review considered audited FY25 and unaudited 9MFY26 financial results.Term loans from HDFC Bank and SBI account for ₹243.72 crore of the total long-term facilities.
👀 கவனிக்க வேண்டியவை
The 'Positive' outlook indicates a high probability of a rating upgrade if the company maintains its current growth trajectory. Investors should view this as a sign of improving financial health which could lead to lower borrowing costs in the future.
Innova Captab Limited has successfully contested a tax demand from the CGST Commissionerate, Shimla. The adjudicating authority dropped the proposed demand of ₹15.81 crore and all associated penal proceedings. The company had filed its response to the October 2025 Show Cause Notice with supporting documents which were found legally sustainable. This concludes the matter with zero liability, removing a significant potential financial hit to the company's balance sheet.
முக்கிய அம்சங்கள்
CGST Commissionerate dropped a tax demand totaling ₹15.81 crore.The demand was originally raised under Section 74 of the CGST Act, 2017.The adjudicating authority found the company's legal submissions valid and sustainable.The matter is now fully concluded with no financial liability or penalties for Innova Captab.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive resolution of a significant contingent liability. No further action is required as the legal risk has been successfully mitigated.
Innova Captab reported a strong Q3 FY26 with consolidated revenue growing 42.3% YoY to ₹450.3 crores, driven by a massive 79% surge in the branded generics segment. The CDMO business also showed steady growth of 29% YoY, contributing ₹298.7 crores to the top line. The newly commissioned Jammu facility is scaling up well, contributing ₹89 crores this quarter and nearing EBITDA break-even. Profitability remained robust with EBITDA rising 39.6% to ₹71.1 crores, maintaining a healthy margin of 15.8%.
முக்கிய அம்சங்கள்
Consolidated Q3 revenue reached ₹450.3 crores, a 42.3% YoY increase from ₹316.4 crores.Branded generics segment grew 79% YoY to ₹151.6 crores due to aggressive domestic and international expansion.Jammu facility revenue rose to ₹89 crores from ₹60 crores in the previous quarter, nearing EBITDA break-even.EBITDA increased by 39.6% YoY to ₹71.1 crores with margins steady at 15.8%.Exports formed 35% of Q3 revenue mix, supported by new UK-MHRA and PIC/S certifications.
👀 கவனிக்க வேண்டியவை
Investors should monitor the ramp-up of the Jammu facility, which has a potential revenue capacity of ₹1,400+ crores at optimum utilization. The strong growth in high-margin branded generics and expansion into regulated export markets provides a positive long-term outlook.
Innova Captab Declares ₹2 Interim Dividend; Sets January 30 as Record Date
Innova Captab Limited has declared an interim dividend of ₹2 per equity share, representing 20% of the face value of ₹10 each for FY 2025-26. The company has fixed January 30, 2026, as the record date to determine shareholder eligibility for the payout. In compliance with the Finance Act 2020, the dividend is taxable, and the company will deduct Tax at Source (TDS) based on the residential status and documentation provided by shareholders. Shareholders are required to submit relevant tax forms by 5:00 PM on the record date to ensure appropriate tax treatment.
முக்கிய அம்சங்கள்
Interim dividend declared at ₹2 per equity share (20% of face value).Record date for dividend eligibility is fixed as Friday, January 30, 2026.TDS will be deducted based on documentation submitted via KFintech portal by Jan 30.Dividend payments will be made exclusively through electronic modes like NEFT and RTGS.The board meeting declaring this dividend was held on January 23, 2026.
👀 கவனிக்க வேண்டியவை
Investors should ensure their bank account details are updated with their DP and submit Form 15G/15H by January 30 to minimize TDS impact.
Innova Captab Q3 FY26 Revenue Surges 42% YoY to ₹450 Cr; Branded Generics Up 79%
Innova Captab reported a strong Q3 FY26 with revenue growing 42.3% YoY to ₹450.3 crore, driven by a massive 79% jump in the Branded Generics segment. EBITDA increased by 39.6% to ₹71.1 crore, though margins slightly contracted to 15.8% from 16.1% due to higher employee and material costs. The company achieved significant regulatory milestones, including UK-MHRA and PIC/s GMP certifications, which are expected to boost international market access. The newly commercialized Jammu facility is ramping up, providing a long-term growth runway with significant tax incentives.
முக்கிய அம்சங்கள்
Consolidated Revenue for Q3 FY26 grew 42.3% YoY to ₹450.3 crore, while 9M FY26 revenue reached ₹1,182.2 crore.Branded Generics segment showed stellar performance with 79% YoY growth in Q3, reaching ₹151.6 crore.EBITDA for the quarter rose 39.6% to ₹71.1 crore, maintaining a healthy margin of 15.8%.Export contribution increased to 35% of total revenue in Q3 FY26, supported by new global GMP certifications.The Jammu manufacturing facility, commercialized in Jan 2025, is eligible for GST-linked incentives totaling 300% of investment over 10 years.
👀 கவனிக்க வேண்டியவை
Investors should monitor the capacity utilization ramp-up at the Jammu facility and the margin trajectory as the high-growth Branded Generics business scales. The stock remains a strong play on the Indian CDMO and generic export themes.
Innova Captab reported a strong 42.3% YoY increase in consolidated revenue to ₹4,502.93 million for Q3 FY26. Net profit for the quarter rose 23.2% to ₹421.49 million, while basic EPS improved to ₹7.37 from ₹5.97. The company also declared an interim dividend of ₹2 per share (20% of face value) with a record date of January 30, 2026. For the nine-month period ending December 2025, revenue reached ₹11,822.16 million with a total profit of ₹1,028.34 million.
முக்கிய அம்சங்கள்
Consolidated revenue increased by 42.3% YoY to ₹4,502.93 million in Q3 FY26.Consolidated net profit grew 23.2% YoY to ₹421.49 million for the quarter.Declared an interim dividend of ₹2 per share (20% of face value) for FY 2025-26.9M FY26 revenue reached ₹11,822.16 million, up from ₹9,289.35 million in 9M FY25.Fixed January 30, 2026, as the record date for determining dividend eligibility.
👀 கவனிக்க வேண்டியவை
The strong revenue growth and consistent dividend payout reflect positive operational momentum in the pharmaceutical segment. Investors may consider holding or accumulating on dips, given the double-digit profit growth and healthy cash distribution.
Innova Captab Board to Meet Jan 23 for Q3 Results and Interim Dividend Consideration
Innova Captab Limited has scheduled a board meeting on January 23, 2026, to approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board will also consider a proposal for declaring an interim dividend for the financial year 2025-26. If approved, the company has already fixed January 30, 2026, as the record date to determine shareholder eligibility for the payout. This dual announcement indicates potential cash returns to shareholders alongside the quarterly performance update.
முக்கிய அம்சங்கள்
Board meeting scheduled for January 23, 2026, to review Q3 and 9M FY26 financial performance.Proposal for an interim dividend for FY 2025-26 to be considered during the meeting.Record date for the potential interim dividend is fixed as January 30, 2026.Trading window for insiders remains closed from January 1, 2026, until 48 hours after the results are declared.
👀 கவனிக்க வேண்டியவை
Investors should monitor the January 23 announcement for the dividend amount and earnings growth to assess the company's yield and operational health.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
